Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | IL18 | Q14116 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15143918 | 0.86 | SMN1; SMN2 (0.79) | RAB9AHPGDNPC1CYP1A2CYP2D6 | |
| SCHEMBL2088691 | 0.82 | PGR (0.62) | RAB9AHPGDNPC1SMN1; SMN2KDM4E | |
| SCHEMBL19537303 | 0.80 | IDO1 (0.51) | RAB9AKDM4EMAPTMEN1KMT2A | |
| SCHEMBL6415967 | 0.80 | SMN1; SMN2 (0.56) | RAB9ASMN1; SMN2KDM4EMAPTMEN1 | |
| SCHEMBL10192163 | 0.79 | NPC1 (0.69) | RAB9AHPGDNPC1CYP1A2CYP2D6 | |
| SCHEMBL12309897 | 0.77 | PGR (0.56) | RAB9AHPGDNPC1CYP1A2CYP2C9 | |
| SCHEMBL17904708 | 0.77 | NPC1 (0.67) | RAB9AHPGDNPC1CYP1A2CYP2D6 | |
| SCHEMBL20941550 | 0.77 | MAPT (0.54) | RAB9AKDM4EMAPTMEN1KMT2A | |
| SCHEMBL12996859 | 0.77 | SMN1; SMN2 (0.67) | RAB9AHPGDNPC1CYP1A2CYP2D6 | |
| SCHEMBL13513998 | 0.77 | RAB9A (0.67) | RAB9AHPGDNPC1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1722796-A4 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007117289-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-18 | — | — | WO | disclosed |
| CN-101014343-A | Tetracyclic lactam derivatives and uses thereof | INOTEK PHARMACEUTICALS CORP (US) | 2007-08-08 | — | — | CN | disclosed |
| EP-1722796-A2 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | Inotek Pharmaceuticals Corporation (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-11-24 | — | — | US | disclosed |
| WO-2005082079-A2 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | PARK7, GLS, IAPP | RAB9A 1521/4885HPGD 771/4885NPC1 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.